QNZ46

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

QNZ46 是一种 NR2C/NR2D 选择性 NMDA 受体非竞争性拮抗剂。

QNZ46 is a NMDA receptor antagonist. QNZ46 inhibits NMDA receptor function in a noncompetitive and voltage-independent manner by an unconventional mechanism that requires binding of glutamate to the GluN2 subunit, but not glycine binding to the GluN1 subunit. QNZ46 could provide an opportunity for the development of pharmacological tools and therapeutic agents that target NMDA receptors at a new site and modulate function by a novel mechanism. NMDA receptors are ionotropic glutamate receptors that mediate excitatory synaptic transmission and have been implicated in several neurological diseases.

——

——

QNZ46 | QNZ-46 | QNZ 46

MAPK/ERK Signaling

MEK

NR2A| NR2C| NR2D

Neurological Disease

——

1237744-13-6

443.41

C24H17N3O6

>98% (HPLC)

DMSO : ≥ 4.5 mg/mL10.15 mM

COc1cc2c(cc1)nc(n(c2=O)c1ccc(cc1)C(=O)O)/C=C/c1cc(ccc1)[N+](=O)[O-]

(E)-4-(6-methoxy-2-(3-nitrostyryl)-4-oxoquinazolin-3(4H)-yl)benzoic acid

(-20℃)

With Ice Pack

≥ 2 years